Syngene International has extended its long-term research collaboration with Bristol Myers Squibb (BMS) through 2035, reinforcing a partnership that spans more than two decades.
The renewed agreement expands the scope of collaboration across the entire drug development lifecycle, from early discovery to commercial support.
Under the new term, Syngene will continue to provide integrated, end-to-end services to BMS, including:
The goal is simple: faster program progression, smoother handoffs, and long-term capacity planning.
The Syngene–BMS relationship began in 1998 and led to the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC).
Key milestones:
Today, the centre employs around 700 Syngene scientists working closely with BMS teams.
BBRC supports a wide range of research and development activities, including:
These capabilities support BMS programmes across:
Over the years, BBRC has helped advance multiple compounds from early discovery into first-in-human studies.
The collaboration has delivered:
The agreement signals a shift from project-based outsourcing to long-term strategic partnership.
For Syngene, it reinforces its position as:
For BMS, it ensures continuity, scale, and deep scientific integration to support future pipeline growth.